InDevR Unveils OmniFlu HA Kit to Enhance Influenza Vaccine Development

InDevR, Inc., a leader in vaccine testing, has launched OmniFlu HA, an off-the-shelf kit for influenza vaccine manufacturers. This validated kit targets hemagglutinin (HA) detection and quantification.

The World Health Organization updates influenza strain recommendations yearly. This process typically necessitates analytical method updates, adding to manufacturers' workloads. OmniFlu HA allows simultaneous quantification of four seasonal HA antigens, saving development time.

Built on InDevR's VaxArray® Platform, OmniFlu HA uses over 300 selected influenza antibodies to streamline vaccine testing. It can analyze up to 64 samples in less than two hours, reducing time compared to manual methods.

CEO Kathy Rowen emphasized the product’s role in easing influenza vaccine development. The kit supports various vaccine production methods, including those for mRNA vaccines.

This solution forms part of InDevR's broader portfolio aimed at simplifying vaccine production stages, from early development to potency testing.